Trial Profile
A trial to evaluate efficacy and safety of fingolimod for relapsing-remitting multiple sclerosis, particularly in patients previously exposed to natalizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 04 May 2016 New trial record